

Tuesday 02 May 2017



Today's issue of PD

Pharmacy Daily today has two pages of news plus our Winter Spotlight feature on page 3.

Mayne loses \$200m

MAYNE Pharma shares fell almost 11% on Mon, wiping around \$200m from its market capitalisation, following a revelation that sales for its Teva suite of US generic products would not meet forecasts.

The US generic scene was described by chief executive Scott Richards as "facing a tough price deflation cycle," adding "Mayne Pharma is not immune".

Richards said that the accelerating price pressure is "not just Teva, it's across the sector...this is probably as tough as it's been".

The situation has been worsened by President Donald Trump's classic rhetoric saying that pharma companies "have been getting away with murder," the company said.

\$10m for myDNA

MELBOURNE-BASED myDNA has raised \$10 million in its latest round of capital raising, which has included the backing of Swisse ceo Radek Sali who is joining the genetics company's board.

myDNA chairman Dennis Bastas said "Mr Sali joins our experienced team, bringing a consumer focus to the company's highly credentialed scientific foundations, as we prepare to launch an expanded range of wellness, diet and nutrition tests".

Sali said he believed myDNA represented "the future of health - personalised, tailored health advice that can improve individual health outcomes and allow the health care system to operate more efficiently, all based on robust genetic science".

Code of Conduct update

THE Pharmacy Board of Australia is set to invite feedback to its Code of Conduct for pharmacists in Australia, with social media and online channels to inform the profession on how it can contribute.

Still in an "early research phase," the scheduled review will also feed into the AHPRA framework used by 10 other health profession National Boards, with some minor profession-specific changes for some Boards including Pharmacy.

The Code aims to support and inform good practice, and to assist practitioners, National Boards, employers, health care users and

May PBS additions

HEALTH minister Greg Hunt yesterday confirmed the addition of "\$310 million of new vital drugs" to the Pharmaceutical Benefits Scheme, with new items including Kalydeco (ivacaftor) for children aged 2-5 with cystic fibrosis.

Also now on the PBS is OFEV (nintedanib), a first time treatment for idiopathic pulmonary fibrosis (IPF) from Boehringer Ingelheim.

Hunt also announced the addition of Blincyto (blinatumomab) for acute lymphocytic leukaemia, and Zinbryta (daclizumab) for multiple sclerosis, with the minister saying since coming into government the coalition had added about \$6 billion of new drugs to the PBS "without fear or favour" based on PBAC recommendations.

Winter is (nearly) here

TODAY'S issue of *Pharmacy* **Daily** features our newest Spotlight supplement, with details of several products ideal for winter sales included on page three.

other stakeholders to understand what good practice involves.

"It seeks to assist and support practitioners to deliver safe and effective health services within an ethical framework," according to a communiqué from the Board's latest meeting issued yesterday.

The Board also highlighted the importance of pharmacists meeting legal and professional obligations in relation to advertising (**PD** 21 Apr).

Mar satisfaction

THE latest Customer Satisfaction Awards ratings for community pharmacy from Roy Morgan has seen My Chemist increase its ranking during Mar to 91%.

Terry White came in second place, followed by Priceline Pharmacy, Chemist Warehouse and Soul Pattinson - see roymorgan.com.au.

New MSD biosimilar

RENFLEXIS from the MSD stable is the second infliximab biosimilar to be given TGA approval, and the company is planning a hospital launch of the product in 2017.

The original comparator drug is Remicade from Janssen-Cilag and is approved for autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, psoriasis, Chron's Disease and ulcerative colitis as well as ankylosing spondylitis, each indication carrying their own conditions for prescription.

The first infliximab biosimilar launched in Australia was Hospira's Inflectra.

With a number of originator biologic medicines (primarily mAb therapies) set to come off patent, the government has estimated that increased use of biosimilar medicines will deliver as much as \$880 million in PBS savings over the next five years.

OVER 50% OF YOUR CPD

with one Pharmacy Practice Review ▶





Constantly fishing for customers?

ERS to me





Our **Rëwards** program not only



Tuesday 02 May 2017



Just one click away from keeping up to date with all the **Pharmacy Daily** breaking news as it comes to hand











Dispensary Corner

MY HEART will go on...and on. A couple from New Plymouth in New Zealand are so close that they chose to be admitted to Taranaki Base Hospital with different heart problems.

Ann and Harry Smith both suffered heart attacks on the same night.

Harry, 73, blacked out after having a drink and then Ann, also aged 73, experienced an angina attack - a reduction of blood flow to the heart muscle that imitates the symptoms of a heart attack.

The couple who have been together for half a century, were inseparable via text during their hospital stay, and organised a memorable picture (below) to be snapped by the doctors and nurses who found it all very amusing.



A 58-YEAR old woman from Culiacan, Mexico, has given birth to healthy twins after a second round of IVF, despite high risks of pre-eclampsia for a pregnancy at her advanced age.

According to El Universal, the unnamed new mother had a C-section to deliver twins Victor and Victoria who were then assessed by a paediatrician before spending three weeks in neonatal intensive care.

The babies will undergo months of monitoring to ensure they are developing properly.

The world's oldest mum of twins was 67 year old Maria del Carmen Bousada de Lara from Spain.

DAA services PSA review

THE Pharmaceutical Society of Australia (PSA) is inviting feedback on revised guidelines for Dose Administration Aid services, following a review to support the implementation of new Professional Practice Standards.

The review has focused on Standard 15: Dose Administration Aid (DAA) Service, undertaken to take into account recent research, changes to common practices and the release of the Guidelines on dose administration aids and staged supply of dispensed medicines by the Pharmacy Board of Australia in September 2015.

Comments are sought from stakeholders including pharmacists, consumers, other health professional groups and practitioners, educators, researchers and government bodies.

An important outcome of the review has been updating of the guidance around cytotoxic medicines and medicines stability when repacked in a DAA, in line with recommendations from the Pharmacy Board, as well as Australian and international literature.

The revised guidelines also address advancements in automated packing technology that have developed since the last review in 2007.

The PSA acknowledges the Federal Department of Health for providing funding for this work as part of the PBS Access and Sustainability Package, including the Sixth Community Pharmacy Agreement (6CPA).

Visit psa.org.au to access the consultation paper, including the revised DAA Guidelines.

The consultation will remain open until 24 May 2017 - CLICK HERE.

Orphan drug reform

THE TGA has published transition arrangements for the reform of its Orphan Drug Program, which is two decades.

The program is set to re-focus on "the consideration of greatest unmet need" with additional eligibility criteria targeting lifeconditions, significant benefit over existing options and medical plausibility - see tga.gov.au.

undergoing its first review in almost

threatening or seriously debilitating

Win with dreambaby

This week Pharmacy Daily and Dreambaby® are giving readers the chance to win each day the new Dreambaby® EZY-Reach Organiser

With its generous storage, it's just the thing to store all your must-haves when you're out with little ones. It has two internal drink holders and also comes with a Zip-On, Zip-Off wristlet with headphone access. Available in two colours, black or grey. RRP: \$29.95. #dreambabysafety @dreambabysafety. For more visit www.dreambaby.com.au or call (02) 9386 4000.



To win, be the first person from QLD to send the correct answer to the question below to comp@pharmacydaily.com.au

Congratulations to yesterday's winner, Helle Southwell from Batehaven Pharmacy.

Guild **Update**

New advertising compliance strategy

THE Australian Health Practitioner Regulation Agency (AHPRA) and National Boards have released their new Advertising Compliance and Enforcement Strategy.

AHPRA and National Boards regulate health practitioners in Australia through the National Registration and Accreditation Scheme. The National Scheme regulates 14 health profession groups across Australia.

Their regulatory work includes acting on complaints, educating practitioners and taking action against unlawful advertising.

Their goal is to ensure advertising about regulated health services is done responsibly in order to keep the public safe from false or misleading claims and to assist them to make informed decisions about their healthcare.

The new strategy explains:

- how the risk-based approach is applied to advertising compliance and enforcement
- how they encourage voluntary compliance and deal with non-compliant advertising, and
- how they plan to evaluate and refine this strategy

A dedicated 'advertising resources' section is available on the AHPRA website.

Pharmacy Daily is Australia's favourite pharmacy industry publication. Sign up free at www.pharmacydaily.com.au.

Postal address: PO Box 1010, Epping, NSW 1710 Australia

Street address: Level 2, Suite 1 64 Talavera Rd, Macquarie Park NSW 2113 Australia **P**: 1300 799 220 (+61 2 8007 6760) **F**: 1300 799 221 (+61 2 8007 6769)

Part of the Business Publishing Group.

Publisher/Editor in chief: Bruce Piper Managing Editor: Jon Murrie

Reporter: Mal Smith Contributors: Matt Bell, Rebecca Le Bas, Jasmine O'Donoghue

Advertising and Marketing: Sean Harrigan and Melanie Tchakmadjian advertising@pharmacydaily.com.au Business Manager: Jenny Piper accounts@pharmacydaily.com.au







Editorial: info@pharmacydaily.com.au





Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.



Winter spotlight

Pharmacy Daily's Winter spotlight is your guide to all the essentials - from products to assist with coughs and colds through to keeping you hydrated and vitamin boosted - ready for this years Winter season. To feature here email advertising@pharmacydaily.com.au.

For Winter Relief, Try Flo Nasal Relief! From \$11.95 RRP

If a stuffy nose, blocked sinuses or the sniffles are getting your patients down, help them get some relief with Flo! Flo has a range of preservative-free nasal salines for the family, that clear mucus and wash away germs and irritants, like pollen or dust. So when colds, hayfever, sinusitis or allergies strike, try Flo Saline Plus to help a congested nose or try Flo Sinus Care for a more thorough sinus wash. For younger patients, try Flo Baby or Flo Kids with a gentle spray at any angle delivery system. Flo, the preservative-free nasal relief brand, available only in Pharmacies.

Always read the label. Use as directed. Consult your pharmacist if symptoms persist.

Watch all our adverts here: www.youtube.com Stockists: ENT Technologies 1300 857 912

Website: www.flo.com.au

Demazin Kids Range Cold & Flu from \$12.99 RRP | Cough from \$13.99 RRP

Demazin Kids **Cold & Flu Relief** Liquid for children 2 years+ helps boost immunity to reduce the duration and severity of cold and flu symptoms. Contains Black Elderberry Juice, Zinc and Vitamin C. Demazin Kids **Cough Relief** Liquid helps clear chest congestion and relieves a chesty cough. It is made with ivy leaf extract, a herbal ingredient that helps thin and loosen mucus. Suitable for children 2 years and over.

Always read the label. Use only as directed. If symptoms persist see your healthcare professional.

To order contact: 1800 008 757 or pharmacy.au@bayer.com Download order form HERE Website: www.demazin.com.au

















Pain Strike Oil

From \$11.99 RRP

In the bid for a healthier, pain free lifestyle without the additions of nasty chemicals, PAIN STRIKE OIL has developed a range of natural herbal medicines to aid and assist in the maintenance of general wellbeing and overcoming joint and muscle pain.

Australian owned and operated, PAIN STRIKE OIL contains four active ingredients; Cajuput Oil, Camphor Oil White, Clove Bud Oil and Wintergreen Oil.

Orders can be placed through Symbion or directly from J&T World Trade Pty Ltd Phone 02 9707 1919 Fax: 02 9707 2153 Website: www.painstrikeoil.com.au

Ethical Nutrients Immune Defence 30 Tablets \$29.95 RRP | 60 Tablets \$50.95 RRP

Cough? Runny Nose? Sore Throat?

Help fight the symptoms of cold and flu naturally with Ethical Nutrients Immune Defence. With high strength Andrographis and a complex of immune supporting ingredients including Echinacea and exclusive BCM-95TM Turmeric to support immune response.

Website: www.ethicalnutrients.com.au

Phone: 1800 777 648

Email: orders@healthworld.com.au